Offers slew of incentives for Indian pharma companies
Dubai’s DuBiotech (Dubai Biotechnology and Research Park), one of the top life sciences clusters in the Middle East region embracing the biotechnology, pharmaceutical and medical device, and healthcare technology industries, is entering into an MoU with the Indian Drug Manufacturers’ Association (IDMA).
The MoU will bring to the Indian life sciences community, the opportunities that the Middle East market can offer through the platform of the DuBiotech free zone. The MoU will be signed between Marwan Abdulaziz, Executive Director, Dubai Biotechnology and Research Park (DuBiotech) and Dr Manish Doshi, President, IDMA, in Mumbai on June 15, 2012.
As India has a strong pharma manufacturing industry particularly known for its generics manufacturing, DuBiotech hopes to see more R&D collaborations between Indian companies and Middle East-based academic and clinical expertise. As Indian companies move towards extending their abilities to develop new products, DuBiotech can assist Indian companies to easily access regional networks to connect with institutions and companies with whom they can collaborate for shared benefits.
With a cost-base significantly lower than the global average, a highly-skilled workforce, arguably the best biomedical and pharma infrastructure in the region and ready transport links to the whole of the Middle East, Asia, Europe and the US, the DuBiotech Life Sciences cluster has created itself as a strategically viable location for any aspiring Indian business. The Park offers a conducive environment including an innovative academic and commercial infrastructure where Indian pharma companies can greatly benefit from, and contribute to.
EP News Bureau-Mumbai